The 340B Coalition announced Tuesday that its annual winter conference will be held in person Jan. 31 to Feb. 2, 2022, in San Diego. Its last, pre-pandemic in-person conference was Feb. 10-12, 2020, also in San Diego.
Apexus, the 340B
…
A federal district judge said today she “has a hard time following” the federal government’s argument that the 340B statute requires drug manufacturers to honor covered entities’ drug purchases no matter how entities choose to distribute the medicines.
“It seems
…
A federal district judge has given government lawyers until Wednesday to weigh in on drug manufacturer Sanofi’s request for emergency protection from being brought before a 340B administrative dispute resolution panel.
U.S. Chief District Judge Freda Wolfson gave the U.S.
…
The U.S. Centers for Medicare & Medicaid Services (CMS) final rule that will set what Medicare will pay 340B hospitals for physician-administered drugs next year is another step closer to release.
CMS last week Thursday sent its calendar year
…
Researchers who reported in 2018 that the 340B program leads to hospital-physician practice consolidation but probably not to better care or outcomes for low-income patients have released a new 340B study, this time on hospital provision of uncompensated care. The
…
Pharmaceutical industry vendor Kalderos has asked a federal court to vacate a federal health agency’s policy prohibiting drug manufacturers from conditioning 340B drug discounts on covered entities’ submission of drug claims data.
Kalderos has created a service called 340B
…
Drug manufacturer Sanofi yesterday asked a federal judge in New Jersey to stay 340B administrative dispute resolution (ADR) proceedings against it brought by health centers seeking to overturn Sanofi’s restrictions on 340B pricing when covered entities use contract pharmacies.
Sanofi
…
The U.S. Health Resources and Services Administration (HRSA) told 340B Report yesterday in response to an inquiry that 340B program administrative dispute resolution (ADR) panels have been assigned—signaling that an unknown number of proceedings might begin on ADR petitions by
…
Drug manufacturer Boehringer Ingelheim on Tuesday disputed a federal health agency’s finding a day earlier that BI’s denials of 340B discounts on its drugs when hospitals use contract pharmacies are illegal.
“Boehringer Ingelheim Pharmaceuticals, Inc. is committed to ensuring that its
…*Sign up for news summaries and alerts from 340B Report